A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Key facts
- Where
- Agra, Hyderabad, Kanpur, Kolkata, Mumbai, Mysore, Nashik, Nellore, and Visakhapatna, IndiaSee the 9 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07613307, who can take part
Where in India
- Sarojini Naidu Medical CollegeAgra, IndiaTaking people
- Osmania General HospitalHyderabad, IndiaTaking people
- Brij Medical Centre Pvt. Ltd.Kanpur, IndiaTaking people
- Apollo Multispeciality Hospitals limitedKolkata, IndiaTaking people
- KGN Diabetes and Endocrinology CentreMumbai, IndiaTaking people
- Mysore Medical College and Research InstituteMysore, IndiaTaking people
- Supe Heart & Diabetes Hospital & Research CentreNashik, IndiaTaking people
- Diabetes ClinicNellore, IndiaTaking people
- Visakha Institute of Medical SciencesVisakhapatna, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07613307
- Record updated
- 8 October 2026
- Original description
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.Read full original descriptionShow less
A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.
Inclusion: Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards; Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol/mol)) to less than 9.5% (91 mmol/mol) at screening; Intend to be compliant with the fast during the Ramadan period; Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening; Have body mass index (BMI) of 25 kilograms per meter square (kg/m2) or higher at screening.
Exclusion: Have a history of chronic or acute pancreatitis any time prior to screening; Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes; Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years; Have a history of cholecystectomy (surgically removed gallbladder); Have New York Heart Association Functional Classification IV congestive heart-failure; Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator.